Eosinophilic esophagitis (EoE) is a long-term immune ... There's no cure for EoE. But treatment can help you manage the inflammation that causes symptoms. The main ways to do that are with diet ...

Physicians and patient advocates are sounding the alarm after the NIH abruptly withdrew a grant renewal application for the ...

NS-229 is an investigational selective Janus kinase 1 inhibitor designed to prevent tissue damage caused by EGPA by suppressing immune cell activation.

Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Eupraxia Pharmaceuticals Inc.’s EPRX share price has surged by 5.46%, which has investors questioning if this is right time ...

which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA). NS-229 is being investigated as a selective Janus kinase 1 (JAK1) inhibitor to ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

The APG777 + APG333 combo could bring in around $1.8 billion domestically at similar treatment costs, with global expansion reaching $3.5-$4 billion. Eosinophilic esophagitis, though smaller ...